Malignant carotid body tumors: What we know, what we do, and what we need to achieve. A systematic review of the literature-Reference-Cited by-同舟云学术

Malignant carotid body tumors: What we know, what we do, and what we need to achieve. A systematic review of the literature

Published:2024-01-05 Issue:3 Volume:46 Page:672-687
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head & Neck

Author:

Piazza Cesare¹²,Lancini Davide¹,Tomasoni Michele¹,Zafereo Mark³,Poorten Vincent Vander⁴⁵^ORCID,Hanna Ehab³,Mäkitie Antti A.⁶^ORCID,Fernandez‐Alvarez Veronica⁷,Kowalski Luiz P.⁸,Chiesa‐Estomba Carlos⁹^ORCID,Ferlito Alfio¹⁰

Affiliation:

1. Unit of Otorhinolaryngology – Head and Neck Surgery ASST Spedali Civili of Brescia Brescia Italy

2. Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health University of Brescia, School of Medicine Brescia Italy

3. Department of Head and Neck Surgery MD Anderson Cancer Center Houston Texas USA

4. Otorhinolaryngology – Head and Neck Surgery, Leuven Cancer Institute, University Hospitals Leuven Leuven Belgium

5. Department of Oncology, Section Head and Neck Oncology KU Leuven Leuven Belgium

6. Department of Otorhinolaryngology – Head and Neck Surgery, Research Program in Systems Oncology University of Helsinki and HUS Helsinki University Hospital Helsinki Finland

7. Department of Vascular and Endovascular Surgery Hospital Universitario de Torrecardenas Almeria Spain

8. Department of Head and Neck Surgery University of Sao Paulo Medical School and Department of Head and Neck Surgery and Otorhinolaryngology, AC Camargo Cancer Center Sao Paulo Brazil

9. Department of Otorhinolaryngology – Head and Neck Surgery Donostia University Hospital, Deusto University – School of Medicine, BioGuipuzcoa Research Institute San Sebastian Spain

10. Coordinator of the International Head and Neck Scientific Group Padua Italy

Abstract

AbstractMalignant carotid body tumors (MCBT) are rare and diagnosed after detection of nodal or distant metastases. This systematic review (SR) focuses on MCBT initially approached by surgery. Preferred Reporting Items for SR and Meta‐Analysis (MA) guided the articles search from 2000 to 2023 on PubMed, Scopus, and Web of Science. Among 3548 papers, 132 (337 patients) were considered for SR; of these, 20 (158 patients) for MA. Malignancy rate was 7.3%, succinate dehydrogenase (SDH) mutation 17%, age at diagnosis between 4th and 6th decades, with a higher prevalence of females. MCBTs were mostly Shamblin III, with nodal and distant metastasis in 79.7% and 44.7%, respectively. Malignancy should be suspected if CBT >4 cm, Shamblin III, painful or otherwise symptomatic, at the extremes of age, bilateral, with multifocal disease, and SDHx mutations. Levels II–III clearance should be performed to exclude nodal metastases and adjuvant treatments considered on a case‐by‐case basis.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hed.27624

Reference177 articles.

1. Carotid body tumor: a review;Clairmont AA;Ear Nose Throat J,1977

2. Paragangliomas of the head and neck

3. A Multicenter Review of Carotid Body Tumour Management

4. Carotid body paragangliomas: a systematic study on management with surgery and radiotherapy

5. Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Paragangliomas